Bal Pharma
Bal Pharma Share Price Chart
Bal Pharma last traded at ₹97.71 (2026-10-13). Over the past month the stock moved -7.3%, three months the stock moved +5.5%, year the stock moved +16.3%. Its closing range over 52 weeks is ₹64.01 – ₹114.02, with the latest close 14.3% below the high.
Closing prices up to 2026-10-13.
About Bal Pharma
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]
Business Overview:[1] BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Bal Pharma reported sales of ₹88.62 crore (+34.5%) and net profit of ₹1.13 crore (+438.1%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 88.62 | 7.95 | 8.97 | 1.13 | 0.70 |
| Mar 2026 | 84.08 | 10.58 | 12.58 | 3.60 | 2.25 |
| Dec 2025 | 87.69 | 9.54 | 10.88 | 1.79 | 1.12 |
| Sep 2025 | 74.02 | 5.73 | 7.74 | 0.72 | 0.45 |
| Jun 2025 | 65.87 | 6.06 | 9.20 | 0.21 | 0.13 |
| Mar 2025 | 81.88 | 7.64 | 9.33 | 5.41 | 3.41 |
| Dec 2024 | 73.15 | 7.75 | 10.59 | 0.52 | 0.30 |
| Sep 2024 | 73.69 | 7.69 | 10.44 | 1.04 | 0.65 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -20.4% | -10.4% | -13.5% | -11.4% | +0.4% | +19.9% | +2.7% | +34.5% |
| Operating profit growth | -0.1% | -0.5% | -20.4% | -6.3% | -25.5% | +23.1% | +38.5% | +31.2% |
| Net profit growth | +7.2% | -38.8% | -2.2% | -19.2% | -30.8% | +244.2% | -33.5% | +438.1% |
| EPS growth | +6.6% | -46.4% | -1.4% | -18.8% | -30.8% | +273.3% | -34.0% | +438.5% |
| OPM % | 10.4% | 10.6% | 9.3% | 9.2% | 7.7% | 10.9% | 12.6% | 9.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Bal Pharma reported sales of ₹312.00 crore (+3.0%) and net profit of ₹6.00 crore (-14.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 312.00 | 32.00 | 10.00 | 6.00 | 3.94 |
| Mar 2025 | 303.00 | 30.00 | 10.00 | 7.00 | 4.53 |
| Mar 2024 | 339.00 | 32.00 | 9.00 | 7.00 | 4.68 |
| Mar 2023 | 304.00 | 25.00 | 8.00 | 3.00 | 1.64 |
| Mar 2022 | 281.00 | 24.00 | 9.00 | 6.00 | 3.78 |
| Mar 2021 | 251.00 | 25.00 | 10.00 | 5.00 | 3.20 |
| Mar 2020 | 171.00 | 5.00 | 3.00 | -13.00 | -8.62 |
| Mar 2019 | 225.00 | 18.00 | 8.00 | 2.00 | 2.67 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +6.6% | -24.0% | +46.8% | +12.0% | +8.2% | +11.5% | -10.6% | +3.0% |
| Operating profit growth | +5.9% | -72.2% | +400.0% | -4.0% | +4.2% | +28.0% | -6.3% | +6.7% |
| Net profit growth | – | -750.0% | – | +20.0% | -50.0% | +133.3% | +0.0% | -14.3% |
| EPS growth | +36.2% | -422.8% | – | +18.1% | -56.6% | +185.4% | -3.2% | -13.0% |
| OPM % | 8.0% | 3.0% | 10.0% | 9.0% | 8.0% | 9.0% | 10.0% | 10.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
Bal Pharma is trading at ₹80.28, up 6.8% over 1 month and 35.5% YoY, with strong technical momentum (RSI 65, bullish trend) but fundamentals reveal profitability stress. Net profit has compressed to ₹8 Cr (TTM) from ₹7 Cr (FY25), while net margins have collapsed to 2.6% (TTM) from 2.3% (FY25), and ROCE has fallen from 12% to 10% year-on-year. High leverage (D/E 1.99), minimal FII presence (0.14%), and highly speculative delivery (0.1%) signal structural earnings weakness masked by price momentum.
- Valuation deeply discounted vs industry: P/E 14.75 vs 40.82 industry (63.9% discount), and P/B 1.18 below market average, suggesting significant margin of safety for turnaround investors.
- Strong promoter alignment at 50.86% holding combined with stable shareholding QoQ provides insider confidence and governance stability despite operational headwinds.
- TTM operating margin of 9% demonstrates underlying core business viability in pharmaceutical manufacturing with scope for margin recovery from current depressed net profit levels of 2.6% NPM.
- Structural earnings deterioration: net profit down from ₹7Cr (FY25) to ₹8Cr (TTM) despite revenue of ₹309Cr, with net margins compressed to 2.6% from 2.3% and ROCE fallen 200bps YoY to 10%, signaling operational/cost efficiency challenges that may persist.
- Dangerously high leverage (D/E 1.99) coupled with minimal institutional support (FII 0.14%, delivery % 0.1%) and rising borrowings (₹155Cr vs ₹150Cr YoY) creates refinancing and liquidity risk if operational stress persists; speculative volume alone is sustaining price momentum, not fundamental recovery.
AI-generated analysis for informational purposes only — not SEBI-registered investment advice.
See Full AI Analysis — Free FREE →Latest News
-
Bal Pharma sets 18-month timeline for convertible warrant proceeds - scanx.trade
-
Bal Pharma raises warrant issue price to ₹84 for API expansion - scanx.trade
-
Bal Pharma's Company Secretary & Compliance Officer Abdul Basith Resigns Effective May 11, 2026 - scanx.trade
-
Bal Pharma's Company Secretary & Compliance Officer Abdul Basith Resigns Effective May 11, 2026 - scanx.trade
-
India needs to expand beyond pharma to become global medtech manufacturing hub: Rajesh Agrawal
-
India needs to expand beyond pharma to become global medtech manufacturing hub: Rajesh Agrawal
-
Sun Pharma introduces global innovative drug Ilumya in India to treat psoriasis
-
Zydus Lifesciences Gains USFDA Approval for New Manufacturing Facility, Boosting Global Pharma Expansion
Frequently Asked Questions
What is Bal Pharma's current stock price?
Bal Pharma shares were last quoted at ₹97.71 (+5.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Bal Pharma?
Bal Pharma has a price-to-earnings (P/E) ratio of 23.82 and a price-to-book (P/B) ratio of 2.06. The industry P/E is 53.33.
What is the 52-week high and low of Bal Pharma?
The 52-week high of Bal Pharma is ₹124.68 and the 52-week low is ₹59.69.
What is the market cap of Bal Pharma?
The market capitalisation of Bal Pharma is about ₹171.79 crore.
How did Bal Pharma perform in its latest quarterly results?
In the latest quarter (Jun 2026), Bal Pharma reported sales of ₹88.62 crore (+34.5%) and net profit of ₹1.13 crore (+438.1%), compared with the same quarter last year.
Is Bal Pharma a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Bal Pharma has a 3-year ROE of 9.00%, 3-year profit growth of 35.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Bal Pharma?
Promoters hold about 50.86% of Bal Pharma.
Which sector does Bal Pharma belong to?
Bal Pharma belongs to the Pharmaceuticals & Drugs sector.